Filing summary
Important identity mismatch: The request identifies Riot Platforms, Inc., but the supplied Form 10-Q is for AspenBio Pharma, Inc. This summary reflects the filing text, not Riot Platforms. The filing covers the quarter and nine months ended September 30, 2012; it was signed November 7, 2012.
Business context and reporting period
AspenBio was a development-stage biotechnology company focused principally on AppyScore, a blood-based acute appendicitis diagnostic test, while also licensing animal-health assets. It reported limited antigen-product sales and recurring operating losses. Interim statements are unaudited.
Financial results and liquidity
| Metric | Three months ended September 30, 2012 | Nine months ended September 30, 2012 | Comparable 2011 period |
|---|---|---|---|
| Sales | $6,240 | $40,756 | $22,381 and $175,019, respectively |
| Operating loss | $2.402 million | $6.523 million | $3.011 million and $8.531 million, respectively |
| Net loss | $2.460 million | $6.708 million | $3.063 million and $8.657 million, respectively |
| Net loss per share | $0.32 | $1.78 | $2.29 and $6.46, respectively |
| Operating expenses | $2.412 million | $6.568 million | $3.051 million and $8.743 million, respectively |
Nine-month gross profit was $40,560, or approximately 99.5% of sales; sales were too small to offset operating costs. The filing reports nine-month net cash used in operations of $3.602 million, versus $6.415 million in 2011. Investing activities provided $512,065; financing provided $9.959 million, chiefly from the June stock offering. Cash and cash equivalents at September 30 were $9.837 million, with short-term investments of $389,166, for cash and liquid investments of approximately $10.226 million. Working capital was $6.396 million.
Total liabilities were $6.061 million. Notes and other obligations totaled $3.405 million, of which $2.610 million was classified current. The company’s commercial-bank mortgage portion had an estimated remaining principal balance of approximately $1.578 million due in July 2013; the filing also lists scheduled debt maturities of approximately $2.285 million in 2013.
Material changes versus 2011
- Nine-month sales declined 77% to approximately $41,000, which management attributed mainly to suspending antigen production and redirecting resources to product development.
- Nine-month SG&A declined 10% to $3.945 million; R&D declined 40% to $2.623 million, including lower AppyScore investigational spending after completion of a 2011 pilot trial.
- Net loss narrowed to $6.708 million from $8.657 million, while operating cash use also decreased. The company cautioned that it expected continued losses.
- Common shares outstanding rose substantially following a June 2012 public offering of 6.1 million shares at $2.00 each. Gross proceeds were approximately $12.2 million; offering fees and expenses were $1.261 million. The filing also reports a one-for-six reverse stock split effective June 20, 2012.
- A July animal-health license generated approximately $1.036 million of net deferred revenue; only $4,490 was recognized as revenue through September 30.
Outlook, risks, contingencies, and unusual items
- Management expected cash resources to cover estimated needs for the remainder of 2012 and at least into 2013, but anticipated near-term losses and continued to seek financing. It warned that insufficient new capital could force reduced R&D or cessation of operations.
- Management planned to advance AppyScore toward clinical-trial work and FDA clearance, pursue European CE marking and commercialization, seek partners or licensees, and control costs. The filing provides no quantified revenue or earnings guidance.
- AppyScore depends on successful development and clinical testing, regulatory clearance, manufacturing readiness, and commercialization. Failure to obtain clearance or generate revenue could impair the business and related patent assets. Clinical delays, funding constraints, competition, reimbursement uncertainty, and dependence on third-party manufacturers are cited risks.
- The animal-health license provides for $612,000 in license fees, potential milestone payments of up to $1.1 million plus up to an additional $2 million for additional products, and low-double-digit royalties, subject to contractual conditions and successful milestones/product development.
- Two securities-related cases were dismissed without prejudice in September 2012. Plaintiffs appealed the Wolfe class-action dismissal on October 12, 2012. A related shareholder derivative action remained stayed; a magistrate judge recommended administrative closure, pending court action.
- The company reported recurring losses, negative operating cash flows, and an accumulated deficit of $71.729 million. The filing states the financial statements assume continuation as a going concern and do not include adjustments that might result if the company cannot continue.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is AspenBio Pharma, Inc., not Riot Platforms, Inc.
- Verify AppyScore’s clinical-trial progress, FDA pathway and timing, CE-marking status, and funding needs.
- Assess cash runway against actual operating cash burn, upcoming debt payments, and the availability and terms of additional financing.
- Review the animal-health license’s payment and milestone conditions, amounts remaining collectible, third-party royalty obligations, and revenue-recognition treatment.
- Check the status and potential consequences of the Wolfe appeal and stayed derivative action.
- Reconcile the filing’s debt maturity disclosures and confirm the July 2013 mortgage balloon payment and refinancing or repayment plan.